Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03757130 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
A Phase 1 study of Obesity, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 4
- Study locations
NCT03757130 is a Phase 1 study of Obesity that has completed, run by Amgen. The registered enrollment target is 50 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT03757130, a Phase 1 study of Obesity, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 4
- Study locations
Study Summary
The main objective of this study is to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Liraglutide
- DRUG AMG 598
Study Locations (4)
Alabama
- William D Summers MD LLC - Birmingham
California
- Orange County Research Center - Tustin
Florida
- QPS Miami Research Associates - South Miami
Texas
- Dallas Diabetes and Endocrine Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-11-26 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03757130
The ClinicalTrials.gov registry entry for NCT03757130 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (94% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03757130 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Alabama, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03757130 about?
NCT03757130 is a clinical study titled "Multiple Ascending Dose Study of AMG 598 in Adults With Obesity". The main objective of this study is to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity.
What is the current status of trial NCT03757130?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2018-11-26. Estimated completion is 2019-12-16.
What conditions does trial NCT03757130 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT03757130?
The interventions under investigation include: Placebo (DRUG), Liraglutide (DRUG), AMG 598 (DRUG).
Who is sponsoring clinical trial NCT03757130?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03757130 being conducted?
This trial has 4 study locations across Alabama, California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.